Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Late, late doxorubicin cardiotoxicity

S L Gottlieb, W A Edmiston, L J Haywood

    Chest
    |December 1, 1980
    PubMed
    Summary

    Adriamycin (doxorubicin) can cause heart damage, typically appearing months after treatment. This case highlights a rare instance of cardiomyopathy developing over two years later, indicating very late cardiotoxicity.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Consultation report - gonococcal immunoassays and standards for vaccine development.

    Vaccine·2026
    Same author

    Early efforts of blacks in the fight against heart disease and stroke.

    Journal of the National Medical Association·2000
    Same author

    Social class and recovery from myocardial infarction.

    Annals of internal medicine·1998
    Same author

    Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias.

    Archives of internal medicine·1998
    Same author

    Predictive value of prior Rose angina for myocardial infarction confirmation after emergency admissions.

    Journal of the National Medical Association·1998
    Same author

    Tumor necrosis factor alpha.

    Journal of the National Medical Association·1998

    Area of Science:

    • Oncology
    • Cardiology
    • Pharmacology

    Background:

    • Adriamycin (doxorubicin) is a vital chemotherapy drug.
    • Cardiac toxicity is a significant dose-limiting side effect of adriamycin therapy.
    • Established cardiotoxicity usually manifests within six months post-treatment, often exceeding cumulative doses of 600 mg/m2.

    Observation:

    • A patient presented with progressive cardiomyopathy.
    • The patient had received a cumulative dose of 580 mg/m2 of adriamycin.
    • Cardiac symptoms emerged two and a half years after completing adriamycin treatment.

    Findings:

    • This case represents a delayed onset of adriamycin-induced cardiomyopathy.
    • The patient's presentation suggests a 'late, late' cardiotoxicity phenomenon.
    • The observed cardiotoxicity occurred at a dose below the commonly cited threshold for frequent cardiomyopathy.

    Implications:

    • This case expands the understanding of adriamycin's potential cardiac side effects.
    • It suggests the need for long-term cardiac monitoring in patients treated with adriamycin, even at lower cumulative doses.
    • Further research into the mechanisms of late-onset cardiotoxicity is warranted.

    Related Experiment Videos